QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.106.013425v1 35/3/476    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Endo, T. Articles by Momose, Y. Search for Related Content PubMed PubMed Citation Articles by Endo, T. Articles by Momose, Y.

Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes

Pharmacokinetics Research (T.E., A.Y., Y.H., Y.M.), Process Chemistry (M.B., K.H.), Kissei Pharmaceutical Co., Ltd., Nagano, Japan

(Received October 20, 2006; Accepted December 15, 2006)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Pilocarpine is a cholinergic agonist that is metabolized to pilocarpic acid by serum esterase. In this study, we discovered a novel metabolite in human urine after the oral administration of pilocarpine hydrochloride, and we investigated the metabolic enzyme responsible for the metabolite formation. The structure of the metabolite was identified as 3-hydroxypilocarpine by liquid chromatography-tandem mass spectrometry and NMR analyses and by comparing to the authentic metabolite. To clarify the human cytochrome P450 (P450) responsible for the metabolite formation, in vitro experiments using P450 isoform-selective inhibitors, cDNA-expressed human P450s (Supersomes; CYP1A2, -2A6, -2B6, -2C9, -2C19, -2D6, -2E1, and -3A4), and liver microsomes from different donors were conducted. The formation of 3-hydroxypilocarpine in human liver microsomes was strongly inhibited (>90%) by 200 µM coumarin. Other selective inhibitors of CYP1A2 (furafylline and -naphthoflavone), CYP2C9 (sulfaphenazole), CYP2C19 [(S)-mephenytoin], CYP2E1 (4-methylpyrazole), CYP2D6 (quinidine), and CYP3A4 (troleandomycin) had a weak inhibitory effect (<20%) on the formation. The highest formation activity was expressed by recombinant CYP2A6. The K_m value for recombinant CYP2A6 was 3.1 µM, and this value is comparable with that of human liver microsomes (1.5 µM). The pilocarpine 3-hydroxylation activity was correlated with coumarin 7-hydroxylation activity in 16 human liver microsomes (r = 0.98). These data indicated that CYP2A6 is the main enzyme responsible for the 3-hydroxylation of pilocarpine. In conclusion, we identified a novel metabolite of pilocarpine, 3-hydroxypilocarpine, and we clarified the involvement of CYP2A6 in the formation of this molecule in human liver microsomes.

In this study, we isolated a hydroxylated metabolite from human urine after the oral administration of pilocarpine and identified this by LC-MS/MS¹ and NMR analyses. Moreover, we identified the human P450 responsible for the formation of the novel metabolite 3-hydroxypilocarpine in human liver microsomes.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. Pilocarpine hydrochloride and [imidazol-2-¹⁴C]pilocarpine hydrochloride ([¹⁴C]pilocarpine hydrochloride) were purchased from Sigma-Aldrich (St. Louis, MO) and GE Healthcare (Little Chalfont, Buckinghamshire, UK), respectively. The radiochemical purity of [¹⁴C]pilocarpine hydrochloride was confirmed to exceed 98% (by HPLC). [4-(1-Imidazolyl)-phenyl]oxyacetic acid (internal standard) and 3-hydroxypilocarpine were synthesized by Kissei Pharmaceutical (Nagano, Japan). Coumarin, 7-hydroxycoumarin, troleandomycin, quinidine sulfate salt dihydrate, sulfaphenazole, 4-methylpyrazole hydrochloride, -naphthoflavone, and furafylline were purchased from Sigma-Aldrich. (S)-(+)-Mephenytoin was purchased from Ultrafine Chemicals (Manchester, UK). Glucose 6-phosphate, glucose-6-phosphate dehydrogenase, and NADP⁺ were obtained from Oriental Yeast (Tokyo, Japan). All other reagents were of the highest grade possible. Human liver microsomes were purchased from Xeno Tech (Lenexa, KS). Recombinant human cytochrome P450 isoforms (CYP1A2, -2A6, -2B6, -2C9, -2C19, -2D6, -2E1, and -3A4) expressed in baculovirus-infected insect cells (Supersomes) and control microsomes that had not been transfected (control Supersomes) were purchased from BD Gentest (Woburn, MA).

Isolation of M-1 from Human Urine. Human urine samples were collected from healthy volunteers who participated in a phase I trial of pilocarpine hydrochloride. This study was approved by the Institutional Review Board of the Kitasato Institute Bio-Iatric Center. All volunteers understood the procedures and agreed to participate in the study by giving written informed consent. A single oral dose of pilocarpine hydrochloride (10 mg) was administered to six male volunteers. Urine samples were collected at 0 to 4, 4 to 8, 8 to 12, and 12 to 24 h after the dose and stored at –20°C until analysis. Blank urine samples were collected from the same volunteers before drug administration. Three milliliters of the 0- to 4-h urine sample from each volunteer was pooled and used for the isolation of M-1. The pooled urine was diluted with a 2-fold volume of 10 mM ammonium acetate buffer, pH 5.0. The diluted urine was applied to a Bond-Elute C18 column (500 mg, 3 ml; Varian, Inc., Harbor City, CA), preconditioned by washing with 1.5 ml of methanol and 10 mM ammonium acetate buffer, pH 5.0, washing with 0.5 ml of 10 mM ammonium acetate buffer, pH 5.0, and then eluting with 0.5 ml of methanol/water (4:6, v/v). The eluent was subsequently applied to a Bond-Elute PRS column (100 mg, 10 ml; Varian, Inc.) preconditioned by washing with 1 ml of methanol/water (4:6, v/v). The column was washed with 1 ml of a mixture of methanol and 2 M HCl (98:2, v/v) and 1 ml of methanol. The fraction containing M-1 was eluted with 1 ml of a mixture of methanol and 25% NH₄OH (98:2, v/v). The eluent was dried under a nitrogen stream and then reconstituted in 10 mM ammonium acetate buffer, pH 5.0. The dissolved solution was used for the following isolation using HPLC. The HPLC system consisted of two L-7100 pumps, an L-7400 UV detector, a D-7500 integrator (all from Hitachi, Tokyo, Japan), and an ERC-3215 degasser (ERC, Tokyo, Japan). A Mightysil RP-18 GP column (150 x 4.6 mm i.d.; Kanto Chemicals, Tokyo, Japan) was used for the isolation of M-1. The column temperature was ambient, and the flow rate was 1.0 ml/min. The mobile phase was a mixture of 10 mM ammonium acetate, pH 5.0/acetonitrile (97:3, v/v). After the injection of the reconstituted sample, the eluate containing M-1 was monitored at 214 nm, and the fraction (retention time 6 min) was collected manually. The isolated fraction was evaporated to dryness and stored at –20°C until analysis.

View larger version (14K): [in this window] [in a new window]   FIG. 1. Synthesis of 3-hydroxypilocarpine from pilocarpine.

The isolated M-1 was characterized and identified by NMR spectroscopy. ¹H NMR spectra in deuteromethanol (CD₃OD) were recorded at 500 MHz using a Bruker DRX500 spectrometer (Bruker Instruments Inc., Billerica, MA). The chemical shifts are expressed in parts per million relative to tetramethylsilane or the residual methyl signal (3.30 ppm) of methanol as an internal standard.

Based on the mass spectral and NMR analyses, the proposed structure for M-1 possessed a hydroxyl group on carbon-3 with (R)-stereochemistry. To confirm this structure, an authentic sample was synthesized as shown in Fig. 1. The synthesized (R)- and (S)-diastereomers, namely, 3-hydroxypilocarpine and 3-hydroxyisopilocarpine, were separated on a C18 column. The configuration of the authentic sample was confirmed from its single crystal X-ray diffraction pattern (data not shown).

Incubation of [¹⁴C]Pilocarpine in Human Microsomes. In vitro metabolism was investigated in human liver microsomes using ¹⁴C-labeled pilocarpine. The mixture of [¹⁴C]pilocarpine and nonlabeled pilocarpine (1:1; final 10 µM) was incubated in a reaction mixture made up of 50 mM potassium phosphate buffer, pH 7.4, 1 mg/ml human liver microsomes, an NADPH-generating system (0.8 mM NADP⁺, 8 mM glucose 6-phosphate, 1 U/ml glucose-6-phosphate dehydrogenase, and 5 mM MgCl₂), and 1 mM EDTA in a final volume of 200 µl. The stability of pilocarpine in the reaction mixture consisted of 50 mM potassium phosphate buffer, pH 7.4, and human liver microsomes was also investigated. The reaction was initiated by the addition of microsomes after a 3-min preincubation at 37°C. After a 60-min incubation, the reaction was stopped by the addition of 0.8 ml of ice-cold acetonitrile. After centrifugation (16,000g for 2 min at 4°C) of the mixture, the supernatant was evaporated under a stream of nitrogen gas at room temperature and reconstituted in 10 mM ammonium acetate buffer, pH 5.0. The metabolites were analyzed by HPLC as described under LC-MS/MS and NMR Analyses. The radioactivity in the column eluate was detected by the use of a radiochemical detector (Radiomatic 525TR; PerkinElmer Life and Analytical Sciences, Boston, MA). The detected metabolite was analyzed by LC-MS/MS as described above, with the modification that the precursor ion was m/z 227 (¹⁴C) instead of m/z 225.

Pilocarpine 3-Hydroxylation in Human Liver Microsomes. The generation of 3-hydroxypilocarpine (M-1) in human liver microsomes was conducted under the conditions described above. To establish the optimal reaction time and microsomal protein concentration, the reaction was investigated with the reaction times of 30, 60, 90, and 120 min and with protein concentrations of 0.5, 1.0, and 1.5 mg/ml at a pilocarpine concentration of 10 µM. The amount of production was observed to increase linearly with incubation time and protein concentration. Accordingly, the reaction time and protein concentration were set at 60 min and 1.0 mg/ml, respectively. The pilocarpine concentration was set at 2 µM, with the exception of the enzyme kinetics studies (0.125–25 µM). For the determination of the kinetic parameters (K_m and V_max), an Eadie-Hofstee plot was constructed. The values were used to estimate the apparent kinetic parameters by linear least-squares regression analysis.

Inhibition Study with P450 Isoform-Selective Inhibitors. The following P450 isoform-selective inhibitors were used at the designated concentrations for the inhibition study: -Naphthoflavone (1 µM final concentration) and furafylline (20 µM) for CYP1A2, coumarin (200 µM) for CYP2A6, sulfaphenazole (20 µM) for CYP2C9, (S)-mephenytoin (250 µM) for CYP2C19, quinidine (5 µM) for CYP2D6, 4-methylpyrazole (500 µM) for CYP2E1, and troleandomycin (100 µM) for CYP3A4. Quinidine and 4-methylpyrazole were dissolved in distilled water; -naphthoflavone, coumarin, sulfaphenazole, (S)-mephenytoin, and troleandomycin were dissolved in acetonitrile; and furafylline was dissolved in methanol. The final concentration of the organic solvents was 0.5%. For the competitive inhibition studies with -naphthoflavone, coumarin, sulfaphenazole, (S)-mephenytoin, quinidine, and 4-methylpyrazole, the reaction was initiated by the addition of microsomes after a 3-min preincubation at 37°C. For the mechanism-based inhibition studies with furafylline and troleandomycin, the reaction was initiated by the addition of pilocarpine after a 15-min preincubation at 37°C. The formation activities in the presence of the inhibitors are expressed as a residual percentage of the corresponding control values, in the presence of solvent instead of the inhibitors.

Pilocarpine 3-Hydroxylation by Recombinant P450 Isoforms. To identify the P450 isoforms responsible for the formation of 3-hydroxypilocarpine, microsomes from baculovirus-infected insect cells expressing CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (Supersomes) were used. All the recombinant P450 isoforms were coexpressed with NADPH-cytochrome P450 oxidoreductase; CYP2A6, -2B6, -2C9, -2C19, -2E1, and -3A4 were also coexpressed with cytochrome b₅. The concentrations of pilocarpine and each recombinant P450 isoform in the incubation mixture were 2 µM and 50 pmol/ml, respectively. The other incubation conditions were the same as described above, with the exception that the incubation time was 30 min.

View larger version (22K): [in this window] [in a new window]   FIG. 2. SIM chromatograms of pilocarpic acid, M-1, and pilocarpine from blank urine (A) and from pilocarpine-administered human urine (B). Pilocarpic acid, M-1, and pilocarpine were detected as their protonated molecule ions at m/z 227, 225, and 209, respectively.

Determination of 3-Hydroxypilocarpine Using LC-MS/MS. The concentration of 3-hydroxypilocarpine was determined by LC-MS/MS following acetonitrile precipitation of the incubation mixture. Each of 500-µl aliquots was mixed with 100 µl of 10 ng/ml internal standard (IS) [4-(1-imidazolyl) phenyl] oxyacetic acid. The mixture was evaporated under a stream of nitrogen gas at room temperature and reconstituted in 100 µl of 10 mM ammonium acetate buffer, pH 5.0, containing 2% (v/v) acetonitrile. A 20-µl aliquot was run on a Shimadzu LC-10ADVP system (Shimadzu, Kyoto, Japan). 3-Hydroxypilocarpine and the IS were separated on a CAPCELL PAK C18 MG column (3 µm, 2 x 35 mm; Shiseido, Tokyo, Japan). The column temperature was set at 40°C. The mobile phase consisted of 10 mM ammonium acetate buffer, pH 5.0, containing 2% (v/v) acetonitrile (A) and acetonitrile (B). The initial concentration of B was set at 0%, increased linearly to 70% over 4 min, held for 1 min, and then returned to the initial condition in 0.1 min. The flow rate was maintained at 0.2 ml/min. The HPLC was interfaced with a PE Sciex API-3000 tandem mass spectrometer (Applied Biosystems, Foster City, CA) operated in the positive ionization mode using a turbo ion spray ionization source. The heated nebulizer probe temperature was 550°C, and the turbo ion spray voltage was set at 5000 V. Multiple ion monitoring of the following precursorproduct ion combinations was used for the detection of analytes: 3-hydroxypilocarpine, m/z 225123; and IS, m/z 219160.

Determination of Coumarin 7-Hydroxylation Activity. Coumarin 7-hydroxylation activity was determined as described previously (Greenlee and Poland, 1978; Pearce et al., 1992).

Statistical Analysis. The correlations between pilocarpine 3-hydroxylase activities and coumarin 7-hydroxylase activities in human liver microsomes were determined by the Spearman rank correlation test.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Identification of the Metabolite. In this study, an unidentified metabolite of pilocarpine (M-1) was isolated by HPLC and identified by LC-MS/MS and NMR analyses.

The SIM chromatograms of pilocarpic acid, M-1, and pilocarpine from human urine samples (B) and from the blank urine samples (A) are shown in Fig. 2. Two peaks at m/z 227 with retention times of 1.8 and 3.0 min, corresponding to the pilocarpic acid protonated molecular ion, were detected. The former peak was also detected in the chromatograms of blank urine, suggesting that this peak was derived from an endogenous material. There were two peaks in the SIM chromatogram at m/z 225 corresponding to the M-1 protonated molecular ion with retention times of 5.9 and 7.8 min; these peaks were absent from the blank urine. Two peaks with retention times of 6.0 and ca. 8 min were also detected in the HPLC chromatograms derived from the UV analysis of the samples extracted from pilocarpine-administered human urine (Fig. 3). The major peak with a retention time 6.0 min was considered to be M-1, and this peak was isolated for characterization. Because the peak with a retention time of ca. 8 min made up less than 10% of M-1, no further investigations on this peak were carried out. A pilocarpine peak (m/z 209) was detected in the SIM chromatogram with a retention time of 13.9 min and in the HPLC chromatogram with a retention time of 13.5 min.

View larger version (19K): [in this window] [in a new window]   FIG. 3. HPLC chromatogram of pilocarpine and M-1 extracted from pilocarpine-administered human urine. M-1, retention time 5.97 min; pilocarpine, retention time 13.53 min.

Figure 4, A and B, show the NMR spectra of pilocarpine and the isolated M-1, respectively. The results demonstrated that peak c (2.8 ppm) assigned as the proton "c" of pilocarpine in Fig. 4A disappeared in the NMR chart of M-1 (Fig. 4B). Based on the above-mentioned results, M-1 was conjectured to be the structure in which the site indicated by c had been hydroxylated. In addition, nuclear Overhauser effect analysis was performed to confirm the configuration of the site of hydroxylation. As a result of the irradiation of "b," a nuclear Overhauser effect was observed at the "a," "f," and "d (ß)" protons (data not shown). Based on these results, it was revealed that the carbon atoms at positions b and f take the cis-configuration in M-1 as well as in pilocarpine. Moreover, the result of the NMR analysis of the isolated M-1 was consistent with that of the authentic sample (data not shown). Based on the above-mentioned results, the M-1 found in human urine was identified as a novel metabolite, 3-hydroxypilocarpine.

View larger version (26K): [in this window] [in a new window]   FIG. 4. 1H NMR spectra of pilocarpine (A) and isolated metabolite (M-1) (B) from pilocarpine-administered human urine produced by HPLC fractionation.

View larger version (19K): [in this window] [in a new window]   FIG. 5. Radiochromatograms of the metabolites generated during a 60-min incubation of 10 µM [14C]pilocarpine with human liver microsomes, in the presence (A) or absence (B) of an NADPH-generating system.

Kinetics of 3-Hydroxypilocarpine Formation in Human Liver Microsomes. Figure 6 shows an Eadie-Hofstee plot for the 3-hydroxylation of pilocarpine in pooled human liver microsomes. The plot was almost monophasic and indicated that a single enzyme was responsible for the formation of 3-hydroxypilocarpine from pilocarpine. The apparent K_m and V_max values were 1.5 µM and 8.3 pmol/min/mg, respectively.

View larger version (22K): [in this window] [in a new window]   FIG. 6. An Eadie-Hofstee plot for 3-hydroxypilocarpine formation from pilocarpine in human liver microsomes. Pooled human liver microsomes were incubated with 0.125 to 25 µM pilocarpine at 37°C for 60 min. Each data point represents the mean of duplicate determinations.

View larger version (51K): [in this window] [in a new window]   FIG. 7. Effect of P450 isoform-selective inhibitors on 3-hydroxypilocarpine formation from pilocarpine in human liver microsomes. Microsomes were incubated at 37°C for 60 min with 2 µM pilocarpine in the absence (control) or presence of P450 isoform-selective inhibitors: 1 µM -naphthoflavone, 20 µM furafylline, 200 µM coumarin, 20 µM sulfaphenazole, 250 µM(S)-mephenytoin, 5 µM quinidine, 500 µM 4-methylpyrazole, and 100 µM troleandomycin. Control activities of 3-hydroxypilocarpine formation in the presence of distilled water, methanol, or acetonitrile instead of inhibitors were 3.6, 3.6, and 2.2 pmol/min/mg protein, respectively. Each column represents the mean of duplicate determinations.

View larger version (32K): [in this window] [in a new window]   FIG. 8. Pilocarpine 3-hydroxylation activities of recombinant human P450 isoforms. Pilocarpine (2 µM) was incubated at 37°C for 30 min with each recombinant P450 isoforms (50 pmol/ml) expressed in baculovirus-infected insect cells (Supersomes). Each column represents the mean of duplicate determinations. ND, below the lower limit of quantitation (3.3 fmol/min/pmol P450)

View larger version (24K): [in this window] [in a new window]   FIG. 9. Kinetic analyses of pilocarpine 3-hydroxylation by CYP2A6 Supersomes. CYP2A6 Supersomes were incubated with 0.125 to 25 µM pilocarpine at 37°C for 30 min. Each data point represents the mean of duplicate determinations.

View larger version (27K): [in this window] [in a new window]   FIG. 10. Correlation of 3-hydroxypilocarpine formation and 7-hydroxycoumarin formation in microsomes from 16 human livers. Each data point represents the mean of duplicate determinations.

	Discussion

Top Abstract Materials and Methods Results Discussion References

In human urine samples after the oral administration of pilocarpine, a significant amount of unidentified metabolite was detected on the SIM chromatogram at m/z 225 (Fig. 2). This metabolite was identified as 3-hydroxypilocarpine by both LC-MS/MS and ¹H NMR analyses. Based on the HPLC analysis with UV detection, 3-hydroxypilocarpine seems to be one of the major metabolites of pilocarpine. A minor peak, also detected on the SIM chromatogram at m/z 225 and the HPLC-UV chromatogram with a retention time approximately 8 min, is also thought to be a metabolite of pilocarpine. The amount of this metabolite was less than 10% 3-hydroxypilocarpine, and the effect on the metabolic clearance of pilocarpine is considered to be insignificant. Since the diastereomer of 3-hydroxypilocarpine (i.e., 3-hydroxyisopilocarpine) was separated at an earlier time than 3-hydroxypilocarpine under the separation conditions used (data not shown), the minor metabolite seems to be a novel metabolite hydroxylated at other carbon positions. These findings indicated that pilocarpine is metabolized to 3-hydroxypilocarpine (3R-configuration) but not to 3-hydroxyisopilocarpine (3S-configuration); therefore, the hydroxylation was demonstrated to be highly stereoselective. The degradation of pilocarpine by epimerization to isopilocarpine and hydrolysis to isopilocarpic acid and pilocarpic acid in ophthalmic solutions has been reported (Kreienbaum and Page, 1986); however, isopilocarpine and isopilocarpic acid were not detected on the SIM chromatograms. This result suggests that epimerization to isopilocarpine and its subsequent hydrolysis do not occur in vivo. Therefore, the degradation and/or metabolism to isopilocarpine and isopilocarpic acid are not the key to understanding the high-plasma clearance of pilocarpine.

In the study of in vitro metabolism in human liver microsomes using [¹⁴C]pilocarpine, the only metabolite generated was 3-hydroxypilocarpine. The metabolism required NADPH, and this suggests that P450 is involved in the hydroxylation. Pilocarpic acid and other metabolites were not detected in human liver microsomes, regardless of the presence or absence of an NADPH-generating system. Carboxylesterase is present in human liver microsomal fractions, and it is known to hydrolyze carboester, thioester, and the amide bonds of endogenous and exogenous compounds (Hosokawa et al., 1995). Our results suggest that P450 and carboxylesterase in human liver microsomes are not involved in the hydrolysis of pilocarpine. It was reported that pilocarpine is hydrolyzed in the serum and aqueous humor of rabbits and humans (Ellis et al., 1972; Aromdee et al., 1996). The hydrolysis in serum was strongly inhibited by EDTA and p-chloromercuribenzoic acid (Lavallee and Rosenkrantz, 1965). Recently, Li et al. (2005) reported that butyrylcholinesterase (EC3.1.1.8), paraoxonase (EC3.1.8.1), and albumin esterase (EC3.1.1.7), but not carboxylesterase (EC3.1.1.1), are present in human plasma. Paraoxonase hydrolyzes many lactone compounds, including lactone-containing drugs, such as simvastatin, lovastatin, and spironolactone (Billecke et al., 2000; Khersonsky and Tawfik, 2005). The hydrolytic activity was strongly inhibited by EDTA (Gan et al., 1991; Kuo and La Du, 1995). These properties are similar to those of pilocarpine esterase and suggest that pilocarpine esterase is synonymous with paraoxonase.

An Eadie-Hofstee plot for 3-hydroxypilocarpine formation in human liver microsomes revealed that a single enzyme is predominantly involved. The K_m value was comparable with that of recombinant CYP2A6. In the inhibition study using P450 isoform-selective inhibitors, only coumarin strongly inhibited 3-hydroxypilocarpine formation. In addition, a strong correlation was observed between pilocarpine 3-hydroxylation activity and coumarin 7-hydroxylation activity, the latter of which is an in vitro probe for CYP2A6 activity. These data strongly support the assumption that CYP2A6 is the main enzyme responsible for the formation of 3-hydroxypilocarpine from pilocarpine in human liver microsomes. It is established that pilocarpine is an inhibitor of CYP2A6 (i.e., coumarin 7-hydroxylase activity; K_i = 1–4 µM) (Kinonen et al., 1995; Bourrié et al., 1996; Li et al., 1997); however, although pilocarpine competitively inhibits coumarin-7-hydroxylase activity, it was previously believed that pilocarpine is not a substrate for CYP2A6. Moreover, the only metabolite identified is pilocarpic acid generated by hydrolysis. In the present study, however, we revealed that pilocarpine is not only an inhibitor of CYP2A6 but also a substrate for CYP2A6.

The pilocarpine C_max value (normalized to 5-mg doses) after a single oral administration of pilocarpine to subjects was approximately 20 to 30 ng/ml (0.08–0.12 µM) in plasma (St. Peter et al., 2000). The liver concentration of radioactivity was 10 times higher than that of plasma after a single oral administration of [¹⁴C]pilocarpine to rats (Omori et al., 2004), and the protein binding of pilocarpine in human plasma seems to be less than 5% (van de Merbel et al., 1998). The pilocarpine concentration in the human liver was estimated under the assumption that its liver/plasma ratio in humans is similar to that in rats, and the value was close to the K_m value for the 3-hydroxylation of pilocarpine. This suggests that CYP2A6 is involved in the metabolism of pilocarpine in vivo. In the human liver, CYP2A6 comprises 4% of the total P450 (Shimada et al., 1994), whereas it is not detectable in the human intestine (Paine et al., 2006). Orally administered pilocarpine is assumed to be primarily metabolized to 3-hydroxypilocarpine by CYP2A6 in the liver. The unchanged pilocarpine delivered to the systemic circulation would then be metabolized to pilocarpic acid by esterase. These metabolites are assumed to be excreted into the urine because of their relatively low molecular weight and low protein binding. It has been reported that approximately 35% of dosed 3-hydroxypilocarpine and 20% of dosed pilocarpine were excreted into urine (Aromdee et al., 1999), and approximately equal amounts of pilocarpic acid and pilocarpine were detected in urine (van de Merbel et al., 1998). These data are consistent with our results obtained from the SIM and HPLC chromatograms of urine samples.

St. Peter et al. (2000) reported that no significant regression relationships were noted between creatinine clearance and the pilocarpine elimination rate constant, time of maximum concentration, volume of distribution, clearance, or area under the curve, whereas Garg et al. (1996) reported that the area under the curve and clearance were significantly changed in the subjects with hepatic impairment compared with normal subjects. This suggests that the contribution of metabolic clearance in the liver to the clearance of pilocarpine is more significant than that of renal clearance. Because 3-hydroxypilocarpine is the main metabolite accounting for at least one third of the administered pilocarpine in humans and it is produced by first-pass metabolism in the liver, the 3-hydroxylation of pilocarpine by CYP2A6 is thought to play a major role in pilocarpine clearance.

It has been demonstrated that CYP2A6 is involved in the metabolism of coumarin (Miles et al., 1990), nicotine (Nakajima et al., 1996), tegafur (Komatsu et al., 2000), SM-12502 (Nunoya et al., 1996), and caffeine (Kimura et al., 2005). In humans, a large individual variation has been demonstrated for CYP2A6 activity (Rautio et al., 1992), and it has been revealed that CYP2A6 gene polymorphism is involved in this variation (Nakajima et al., 2001). After the oral administration of pilocarpine to subjects, relatively large individual variations of clearance (5.5-fold difference) were observed (St. Peter et al., 2000). Based on the results in the present study, CYP2A6 is suggested to be significantly involved in the clearance of pilocarpine, and the pilocarpine clearance might be affected by the genetic polymorphism of the CYP2A6 gene.

	Acknowledgments

 
We thank Drs. Tsuyoshi Yokoi and Miki Nakajima (Kanazawa University, Kanazawa, Japan) for help and advice in preparing this article.

	Footnotes

 
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

doi:10.1124/dmd.106.013425.

ABBREVIATIONS: LC-MS/MS, liquid chromatography-tandem mass spectrometry; HPLC, high-performance liquid chromatography; SIM, selected ion monitoring; P450, cytochrome P450; SM-12502, (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.

Address correspondence to: Prof. Takuro Endo, Pharmacokinetics Research, Kissei Pharmaceutical Co., Ltd., 19-48 Yoshino Matsumoto-city, Nagano 399-8710, Japan. E-mail: takuro_endo{at}pharm.kissei.co.jp

	References

Top Abstract Materials and Methods Results Discussion References

 


Aromdee C, Fawcett JP, Ferguson MM, and Ledger R (1996) Serum pilocarpine esterase activity and response to oral pilocarpine. Biochem Mol Med 59: 57–61.[CrossRef][Medline]

Aromdee C, Ferguson MM, Ledger R, and Wall J (1999) A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci 8: 81–83.[CrossRef][Medline]

Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335–1342.[Abstract/Free Full Text]

Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277: 321–332.[Abstract/Free Full Text]

Ellis PP, Littlejohn K, and Deitrich RA (1972) Enzymatic hydrolysis of pilocarpine. Investig Ophthalmol 11: 747–751.[Abstract/Free Full Text]

Gan K, Smolen A, Eckerson HW, and La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100–106.[Abstract]

Garg DC, Lasseter KC, Shrotriya RC, Shamblen EC, Shamblen S, Hoff JV, and Gallagher SC (1996) Pharmacokinetic profile of pilocarpine hydrochloride in subjects with impaired hepatic function (Abstract). Clin Pharmacol Ther 59: 200.

Greenlee WF and Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205: 596–604.[Abstract/Free Full Text]

Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, and Satoh T (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23: 1022–1027.[Abstract]

Hoyng PF and van Beek LM (2000) Pharmacological therapy for glaucoma: a review. Drugs 59: 411–434.[CrossRef][Medline]

Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, and Gallagher SC (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329: 390–395.[Abstract/Free Full Text]

Khersonsky O and Tawfik DS (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44: 6371–6382.[CrossRef][Medline]

Kinonen T, Pasanen M, Gynther J, Poso A, Järvinen T, Alhava E, and Juvonen RO (1995) Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. Br J Pharmacol 116: 2625–2630.

Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, and Kamataki T (2005) CYP2A6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos 33: 1361–1366.[Abstract/Free Full Text]

Komatsu T, Yamazaki H, Shimada N, Nakajima M, and Yokoi T (2000) Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 28: 1457–1463.[Medline]

Kreienbaum MA and Page DP (1986) Stability of pilocarpine hydrochloride and pilocarpine nitrate ophthalmic solutions submitted by U.S. hospitals. Am J Hosp Pharm 43: 109–117.[Abstract]

Kuo CL and La Du BN (1995) Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos 23: 935–944.[Abstract]

Lavallee WF and Rosenkrantz H (1965) Evidence for pilocarpine transformation by serum. Biochem Pharmacol 15: 206–210.[CrossRef]

Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, and Lockridge O (2005) Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70: 1673–1684.[Medline]

Li Y, Li N, and Sellers EM (1997) Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur J Drug Metab Pharmacokinet 22: 295–304.[Medline]

Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, and Wolf CR (1990) Identification of the human liver microsome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 267: 365–371.[Medline]

Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, and Yokoi T (2001) Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 69: 72–78.[CrossRef][Medline]

Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24: 1212–1217.[Abstract]

Nunoya K, Yokoi T, Kimura K, Kodama T, Funayama M, Inoue K, Nagashima K, Funae Y, Shimada N, Green C, et al. (1996) (+)-Cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther 277: 768–774.[Abstract/Free Full Text]

Nyarady Z, Nemeth A, Ban A, Mukics A, Nyarady J, Ember I, and Olasz L (2006) A randomized study to assess the effectiveness of orally administered pilocarpine during and after radiotherapy of head and neck cancer. Anticancer Res 26: 1557–1562.[Abstract/Free Full Text]

Omori Y, Endo T, Hara Y, Nishiyama M, Midgley I, Smart CI, John AJ, Chasseaud LF, McBurney A, and John BA (2004) Absorption, distribution and excretion of ¹⁴C-pilocarpine following oral administration to rats. Arzneim-Forsch/Drug Res 54: 171–178.

Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "PIE". Drug Metab Dispos 34: 880–886.[Abstract/Free Full Text]

Pearce R, Greenway D, and Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298: 211–225.[CrossRef][Medline]

Rautio A, Kraul H, Kojo A, Salmela E, and Pelkonen O (1992) Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2: 227–233.[CrossRef][Medline]

Rhodus NL and Schuh MJ (1991) Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 72: 545–549.[CrossRef][Medline]

Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414–423.[Abstract/Free Full Text]

St. Peter JV, Lambrecht LJ, Gunderson BW, Andersen SA, Gallagher SC, and Swan SK (2000) Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function. J Clin Pharmacol 40: 1470–1475.[Abstract]

Tanzer JM, Kramer PA, Schulman P, and Willard AK (1995) A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. J Dent Res 74: 1845–1849.[Abstract/Free Full Text]

van de Merbel NC, Tinke AP, Oosterhuis B, Jonkman JH, and Bohle JF (1998) Determination of pilocarpine, isopilocarpine, pilocarpic acid and isopilocarpic acid in human plasma and urine by high-performance liquid chromatography with tandem mass spectrometric detection. J Chromatogr Biomed Appl 708: 103–112.[CrossRef]

This article has been cited by other articles:

				R. E. Savage, A. N. Tyler, X.-S. Miao, and T. C. K. Chan Identification of a Novel Glucosylsulfate Conjugate as a Metabolite of 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, {beta}-Lapachone) in Mammals Drug Metab. Dispos., April 1, 2008; 36(4): 753 - 758. [Abstract] [Full Text] [PDF]

				G. Chen, R.-A. Cue, K. Lundstrom, J. D. Wood, and O. Doran Regulation of CYP2A6 Protein Expression by Skatole, Indole, and Testicular Steroids in Primary Cultured Pig Hepatocytes Drug Metab. Dispos., January 1, 2008; 36(1): 56 - 60. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.106.013425v1 35/3/476    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Endo, T. Articles by Momose, Y. Search for Related Content PubMed PubMed Citation Articles by Endo, T. Articles by Momose, Y.